289 related articles for article (PubMed ID: 30281887)
1. DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
Warner EW; Yip SM; Chi KN; Wyatt AW
BJU Int; 2019 May; 123(5):769-776. PubMed ID: 30281887
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
3. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
4. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
[TBL] [Abstract][Full Text] [Related]
5. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
[TBL] [Abstract][Full Text] [Related]
6. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
Castro E; Mateo J; Olmos D; de Bono JS
Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
[TBL] [Abstract][Full Text] [Related]
8. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
9. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
Shore N; Oliver L; Shui I; Gayle A; Wong OY; Kim J; Payne S; Amin S; Ghate S
J Urol; 2021 Apr; 205(4):977-986. PubMed ID: 33332152
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.
Cimadamore A; Cheng L; Massari F; Santoni M; Pepi L; Franzese C; Scarpelli M; Lopez-Beltran A; Galosi AB; Montironi R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073818
[TBL] [Abstract][Full Text] [Related]
11. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer.
Mouw KW; Choudhury AD
Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133
[TBL] [Abstract][Full Text] [Related]
12. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies for DNA repair-deficient prostate cancer.
Teply BA; Antonarakis ES
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):889-898. PubMed ID: 28573914
[TBL] [Abstract][Full Text] [Related]
14. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
Catalano M; Lapucci A; Nobili S; De Gennaro Aquino I; Vascotto IA; Antonuzzo L; Villari D; Nesi G; Mini E; Roviello G
Cancer Chemother Pharmacol; 2024 Jan; 93(1):1-9. PubMed ID: 37934252
[TBL] [Abstract][Full Text] [Related]
15. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
17.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
18. Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications.
Saeidi H; Bakrin IH; Raju CS; Ismail P; Saraf M; Khairul-Asri MG
Adv Med Sci; 2023 Sep; 68(2):359-365. PubMed ID: 37757663
[TBL] [Abstract][Full Text] [Related]
19. BRCAness and prostate cancer: diagnostic and therapeutic considerations.
Dhawan M; Ryan CJ
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):488-498. PubMed ID: 30131605
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]